Lisa M. Coussens

Matrix metalloproteinase inhibitors and cancer: trials and tribulations.

RECKing MMP function: implications for cancer development.

MMP9 potentiates pulmonary metastasis formation.

Inflammation and cancer.

Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment.

Immune enhancement of skin carcinogenesis by CD4+ T cells.

The tumor microenvironment: a critical determinant of neoplastic evolution.

TIMP-1 alters susceptibility to carcinogenesis.

Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment.

Matrix metalloproteinase-2 and -9 expression increases in Mycoplasma-infected airways but is not required for microvascular remodeling.

Cancer: an inflammatory link.

Early neoplastic progression is complement independent.

Soluble mediators of inflammation during tumor development.

The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent.

De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.

Paradoxical roles of the immune system during cancer development.

Inflammation, proteases and cancer.

The inflammatory tumor microenvironment and its impact on cancer development.

A selective activity-based probe for the papain family cysteine protease dipeptidyl peptidase I/cathepsin C.

Analysis of immune cell infiltrates during squamous carcinoma development.

Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC.

Immune cells as anti-cancer therapeutic targets and tools.

Humoral immunity, inflammation and cancer.

IKKalpha at the crossroads of inflammation and metastasis.

Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development.

Hu/Mu ProtIn oligonucleotide microarray: dual-species array for profiling protease and protease inhibitor gene expression in tumors and their microenvironment.

Distinctive features of angiogenesis and lymphangiogenesis determine their functionality during de novo tumor development.

Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression.

Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling.

Tumor stroma and regulation of cancer development.

Immune cells as mediators of solid tumor metastasis.

The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.

Polarized immune responses differentially regulate cancer development.

Genetic and cellular mechanisms of oncogenesis.

Inflaming gastrointestinal oncogenic programming.

Three-dimensional visualization of blood and lymphatic vasculature in tissue whole mounts using confocal microscopy.

Development of an optimized activatable MMP-14 targeted SPECT imaging probe.

Delineating protease functions during cancer development.

CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.

Collagen-based cell migration models in vitro and in vivo.

Optical imaging of the peri-tumoral inflammatory response in breast cancer.

Lymphocytes in cancer development: polarization towards pro-tumor immunity.

FcRgamma activation regulates inflammation-associated squamous carcinogenesis.

Stromal regulation of vessel stability by MMP14 and TGFbeta.

Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.

Cancer and inflammation: promise for biologic therapy.

Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity.

Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression.

Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response.

Leukocytes in mammary development and cancer.

The tumor-immune microenvironment and response to radiation therapy.

Histamine restricts cancer: nothing to sneeze at.

Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization.

Protective role of cathepsin L in mouse skin carcinogenesis.

B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis.

MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles.

Leukocyte composition of human breast cancer.

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

Immune microenvironments in solid tumors: new targets for therapy.

Differential macrophage programming in the tumor microenvironment.

Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines.

Tumor microenvironment complexity: emerging roles in cancer therapy.

Accessories to the crime: functions of cells recruited to the tumor microenvironment.

MR imaging of tumor-associated macrophages.

Neutralizing tumor-promoting chronic inflammation: a magic bullet?

B cells and their mediators as targets for therapy in solid tumors.

Some DCs are "B"etter.

Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma.

Cathepsin C is a tissue-specific regulator of squamous carcinogenesis.

Dendritic cells, inflammation, and breast cancer.

Poker face no more: cancer recurrence reveals its hand.

CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells.

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.

Mammary gland involution as an immunotherapeutic target for postpartum breast cancer.

Manipulating microRNAs to regulate macrophage polarization in gliomas.

Duality of the immune response in cancer: lessons learned from skin.

Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.

TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy.

Macrophages and therapeutic resistance in cancer.

Myeloid Cells as Targets for Therapy in Solid Tumors.

Senescence and cancer: An evolving inflammatory paradox.

Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance.

Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer.

Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.

The Basis of Oncoimmunology.

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

Alk5 inhibition increases delivery of macromolecular and protein-bound contrast agents to tumors.

AACR Cancer Progress Report 2016.

Trim32 Deficiency Enhances Th2 Immunity and Predisposes to Features of Atopic Dermatitis.

MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment.

Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions.

Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis.

Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.